Noxopharm Limited (ASX:NOX) Managing Director and CEO Dr Graham Kelly discusses the company's clinical trial strategy for its lead oncology drug candidate NOX66 with radiotherapy, and the potential market opportunity at FNN's Investor Event.
Investment objective and strategy
NOX66 is potentially a first-in-class, dual-action radio-enhancer
Blocks cell division – makes DNA more susceptible to radiation
Increases killing effect of radiation by 2-3 times
With radiation, showing early efficacy clinically with prostate cancer; pre-clinically with lung, breast, brain cancer cells.
For more, watch Managing Director and CEO Dr Graham Kelly present.